Direction Centrale Du Service De Sante Des Armees — Clinical Trial Site

32 Registered trials

10 Currently recruiting

Organisation

Direction Centrale Du Service De Sante Des Armees

Location

Saint-Mande, France

Identifier

ORG-100013682

Address

Rue Colonel Fonferrier, 29200, France

Departments

#40246: Service de dermatologie
2302: Respiratory
94160
Département Respiratoire
Dermatology
Dermatology Department
HEMATOLOGIE
Médecine interne
Medical Oncology
N/A
Neurologie
Oncologie médicale
ONCOLOGY
Oncology / clinical research Unit
Oncology- pulmonology department
Pneumologie
Pneumology
Pulmonology service
Rheumatology
Service d'Oncologie
Service d'oncologie medicale
Service d’anesthésie Réanimation
Service de médecine interne
Service de pneumologie
Unité de Recherche Clinique

Clinical trials at this site (32)

Search interface

Topical Clobetasol Propionate for Inflammatory Hand osteoarthritis: A randomized trial versus placebo.(PROCLAME) Not authorised

2025-520678-20-00 Adult patients with symptomatic and inflammatory Hand o 5
MAINRITSys : Rituximab vs placebo for maintenance in systemic sclerosis – interstitial lung disease Pending

2025-521331-36-00 Patient with stabilized SSc-ILD (as defined by a declin 10
Trial of Two Adagrasib Dosing Regimens in NSCLC with KRAS G12C Mutation Recruiting

2023-503523-25-00 Non-small cell lung cancer 4 2024-02-29
A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Pati… Recruiting

2022-502959-54-00 Locally Advanced or Metastatic Non-Small Cell Lung Canc 5 2023-09-26
A trial to learn how safe Dato-DXd is and how well it works in people with NSCLC that has advanced after receiving osimertinib Recruiting

2024-511362-37-00 Non squamous non-small cell lung cancer (NSCLC) 5 2026-02-18
A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with moderate to severe hid… Recruiting

2025-520564-17-00 Hidradenitis suppurativa (HS) 5 2025-10-16
Free regimen of Dexamethasone as initial therapy for advanced relapsed/refractory multiple myeloma: an open-label randomized, non-inferiorit… Recruiting

2024-510981-18-00 Multiple Myeloma Multiple myeloma (MM) is a B cell mali 5 2024-12-12
A phase 3 trial comparing a therapeutic cancer vaccine OSE2101 to chemotherapy docetaxel in patients with metastatic Non-Small Cell Lung Can… Recruiting

2023-509340-10-00 Patients with HLA-A2 positive phenotype and metastatic 5 2024-10-29
Clinical trial comparing MK-2870 given with pembrolizumab to pembrolizumab alone in participants who have had surgery for NSCLC Recruiting

2023-508012-35-00 Newly diagnosed NSCLC with resectable clinical Stage II 5 2024-10-02
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered-Dose Inhaler on Cardiopulmonary Outcomes in C… Recruiting

2023-507407-59-00 Chronic Obstructive Pulmonary Disease (COPD) 5 2024-07-04
StAtins for Venous Event Reduction in Patients with Venous Thromboembolism : The SAVER Trial Recruiting

2023-504486-23-00 Venous thromboembolism 5 2024-05-29
Short Treatment With Omalizumab for Severe Asthma (SHORTEN) Recruiting

2024-513427-17-00 Well controlled severe allergic asthma 6 2021-05-20
A clinical study of tulisokibart in people with hidradenitis suppurativa (MK-7240-012) Ended

2024-520039-33-00 Hidradenitis Suppurativa 10 2025-08-11
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Subjects With Progressive Metastatic Castration-… Ended

2024-513968-25-00 Metastatic castration-resistant prostate cancer (mCRPC) 5 2025-04-28
Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis Ended

2023-508235-31-00 Atopic Dermatitis 5 2024-06-17
A Phase 3 Study of Front‑line Platinum Doublet Therapy With Sotorasib Versus Pembrolizumab in PD-L1 Negative KRAS p.G12C Positive Advanced/M… Ended

2022-501863-41-00 Subjects With Stage IV or Advanced Stage IIIB/C Nonsqua 5 2023-11-13
Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic … Ended

2023-509825-38-00 Metastatic Non–Small Cell Lung Cancer 5 2022-12-01
Impact of a treatment with angiotensin receptor blocker on outcome after acute kidney injury in patients discharged from the ICU “START-or-N… Ended

2024-515845-40-00 Acute kidney injury 5 2022-11-22
Phase 1 / 2 Study Evaluating MCLA-129 in Advanced NSCLC Ended

2024-514461-19-00 Solid Tumors 9 2021-09-09
A Clinical Study to Evaluate the Safety and Pharmacokinetics of JNJ- 73841937 (Lazertinib), a Third Generation EGFR-TKI, as Monotherapy or i… Ended

2023-506577-35-00 Advanced Non-Small Cell Lung Cancer 3 2020-09-08
Phase III randomized trial of atezolizumab in elderly patients with advanced Non-Small-Cell Lung Cancer and receiving monthly carboplatin wi… Ended

2024-515946-17-00 Non Small Cell Lung Cancer 5 2019-07-22
Chemo +/- Pembrolizumab (MK-3475) as Perioperative Therapy for Stage II, IIIA-Resectable IIIB (N2) NSCLC Ended

2023-504820-24-00 Neoadjuvant/Adjuvant treatment for participants with Re 5 2018-03-21
An Efficacy and Safety Study of JNJ56021927 (ARN509) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS Ended

2023-505246-26-00 High- or very-high risk, localized or locally advanced 5 2016-01-27
A study to evaluate the efficacy and safety of subcutaneous sonelokimab compared with placebo in adult participants with moderate to severe … Ended

2024-511363-28-00 hidradenitis suppurativa (HS) 5 2024-09-24